ACR Image Metrix Establishes Global Presence
Currently, ACR Image Metrix utilizes three global outposts, providing assistance to those overseas conducting a clinical study. From the birth of the company in 2007 to present, ACR Image Metrix has conducted over 34 trials in North America,more than 28 trials in Europe and over 14 trials in Asia.
The ACR Image Metrix team has worked to complete studies in over 30 countries around the world. ACR Image Metrix has performed site training, evaluation and qualification to multiple centers globally, including Western Europe, North America, South America, South Africa, Middle East (Israel, Saudi Arabia), Eastern Europe, Asia (South Korea, Singapore) and Australia.
ACR Image Metrix specializes in providing imaging CRO services to assist pharmaceutical, biotech and medical device companies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
